Navigation Links
Logical Therapeutics to Present Data on LT-NS001 at American College of Gastroenterology Annual Meeting
Date:10/20/2009

WALTHAM, Mass., Oct. 20 /PRNewswire-USNewswire/ -- Logical Therapeutics, Inc. (Logical), a biopharmaceutical company focused on developing products that treat medical conditions associated with inflammation, has been selected to present the results of its clinical study comparing the gastrointestinal (GI) safety of its lead product LT-NS001, vs. naproxen at the American College of Gastroenterology's (ACG) Annual Scientific Meeting on October 27, 2009.

LT-NS001 is the first in a new class of bio-activated pro-drugs. It is a novel, patented new chemical entity (NCE) pro-drug of the popular non-steroidal anti-inflammatory drug (NSAID) naproxen, which is being developed by Logical Therapeutics to significantly reduce the gastrointestinal (GI) safety risks, including the formation of ulcers, associated with naproxen.

"We are very encouraged by the results of the LT-NS001 vs. naproxen study, and we look forward to sharing them later this month at the ACG meeting," said Peter A. Lankau, chief executive officer of Logical Therapeutics. "This novel, bio-activated pro-drug is being developed to fulfill an unmet need in the marketplace - to provide a single agent capable of delivering relief to those who suffer from chronic inflammatory conditions like arthritis, while significantly improving the GI safety and tolerability as compared to naproxen."

LT-NS001 Well-Tolerated with No Serious Adverse Events

LT-NS001 is unique among NSAIDs as it is pharmacologically inactive as a Cox inhibitor in the GI tract, but once absorbed into the bloodstream, it is converted rapidly and quantitatively to naproxen. In previous clinical studies, LT-NS001 was well-tolerated with no serious adverse events. In pre-clinical testing, LT-NS001 demonstrated significantly less damage to the gastrointestinal tract than equivalent doses of naproxen. Naproxen is widely regarded as the NSAID with the most favorable cardiovascular safety profile among all of the drugs in this class.

In this study, subjects underwent upper endoscopies at baseline and on day seven. Subjects receiving LT-NS001 experienced significantly fewer endoscopically-confirmed gastric ulcers compared to subjects receiving naproxen. The full results from this study will be presented at the American College of Gastroenterology meeting on October 27 in San Diego, Calif.

"In the U.S. alone, the direct costs of treating ulcer complications associated with NSAID use exceed $4 billion annually, and serious complications such as hemorrhage and perforation are directly responsible for approximately 20,000 deaths per year," Lankau said. "LT-NS001 has the potential to help bring down these costs and reduce serious complications for patients whose need for NSAID anti-inflammatory treatment is complicated by significant gastrointestinal risks."

About Logical Therapeutics Inc.

Based in Waltham, MA, Logical Therapeutics, Inc. is a venture-backed, privately held biotechnology company focused on the development of products that treat diseases associated with inflammation. Logical's investors include SV Life Sciences, Burrill and Company, Novo Ventures A/S, and Novitas Capital. For more information on Logical Therapeutics, visit the company's website at www.logicaltx.com.

Please address inquiries regarding LT-NS001 to Logical Therapeutics' business development department at bd@logicaltx.com.

SOURCE Logical Therapeutics, Inc.


'/>"/>
SOURCE Logical Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Article Published in Expert Opinion on Biological Therapy Evaluates StemEx(R) (carlecortemcel-l) for Leukemia and Lymphoma
2. Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrines Cotara(R) for Treatment of Brain Cancer
3. Cytel Signs Cooperative Research And Development Agreement With FDA Center for Devices and Radiological Health (CDRH)
4. Clinical and Histopathological Results Using Pollogens TriPollar(TM) Radio Frequency Technology Published in the June Issue of the Journal of Cosmetic and Laser Therapy
5. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
6. Logical Therapeutics Appoints Peter A. Lankau as CEO and Director
7. Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
8. Genetic Research Leads to New Discovery in Understanding Rare Neurological Disorder
9. Study Shows How Defective DNA Repair Triggers Two Neurological Diseases
10. Neurobiological Technologies Announces Viprinex(TM) Does Not Pass Interim Futility Analysis
11. The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Countrys Biological Preparedness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ROCKVILLE, Md. , Sept. 22, 2017  As ... by Republican Senators Bill Cassidy (R-LA) and ... Kalorama Information notes that the medical device industry is ... the medical device tax, the 2.3% excise tax on ... Act.  But they also want covered patients, increased visits ...
(Date:9/19/2017)... 19, 2017   ZirMed Inc ., a recognized leader ... that it has been ranked #1 by its users for ... Rankings 2017 User Survey. ZirMed was recognized as the top-ranked ... and medical centers over 200 beds and holds one of ... user survey history. ...
(Date:9/13/2017)... has been named the official orthopedic and sports medicine ... 2018 College Football Playoff (CFP) National Championship to be played ... Atlanta, Georgia . OrthoAtlanta is proud to be ... many activities leading up to, and including the national championship ... OrthoAtlanta serves ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for professional ... action towards gender equality at their inaugural Summit in New York City in June. ... a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the Mission ... lost souls in the Philippines. “The Journey: From the Mountains to the Mission Field” ... the Bible. She has taught all ages and currently teaches a class of ladies ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... LOS ANGELES (PRWEB) , ... October 12, 2017 ... ... of Parsa Mohebi Hair Restoration, has recently contributed a medical article to the ... doctors, on cosmetictown.com. Dr. Mohebi’s article spotlights the hair transplant procedure known as ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... first interactive health literacy software tool, and the Cancer Patient Education Network (CPEN), ... patient education, today announce a new strategic alliance. , As CPEN’s strategic ...
Breaking Medicine News(10 mins):